Favorable outcome with chemo-immunotherapy in Burkitt lymphoma and leukemia

Leuk Res. 2009 Apr;33(4):587-8. doi: 10.1016/j.leukres.2008.07.024. Epub 2008 Aug 31.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Burkitt Lymphoma / drug therapy*
  • Burkitt Lymphoma / mortality
  • Burkitt Lymphoma / pathology
  • Child
  • Child, Preschool
  • Cytarabine / administration & dosage
  • Dexamethasone / administration & dosage
  • Female
  • Humans
  • Immunotherapy*
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Neoplasm Staging
  • Rituximab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Cytarabine
  • Rituximab
  • Dexamethasone
  • Methotrexate